FIELD: medicine.
SUBSTANCE: invention relates to medications and deals with pharmaceutical composition, including (i) pharmacologically efficient amounts of each of active substances: a) neutral endopeptidase inhibitor, b) endogenous endothelin-producing system inhibitor, and c) HMG (hydroxymethylglutaryl) CoA reductase inhibitor, selected from the group including atorvastin and simvastatin or any their physiologically acceptable salts, solvates or ethers, where subcombination of neutral endopeptidase inhibitor a) and endogenous endothelin-producing system inhibitor is combination of double action, which is able to inhibit neutral endopeptidase and human soluble endopeptidase, which is represented by daglutril and (ii) preferably pharmaceutically acceptable auxiliary substances and/or carriers, for prevention or treatment of cardiovascular disorders in mammals and humans. Also described is set for prevention and treatment of cardiovascular in mammals and humans.
EFFECT: composition demonstrates synergetic effect in treatment of cardiovascular diseases.
9 cl, 3 tbl, 1 ex
